Safety and Tolerability of Intravitreal SPVN20 Gene Therapy in End-Stage Rod-Cone Dystrophy with Dormant Foveal Cone Photoreceptors

The primary objective of this study is to evaluate the **safety** and **tolerability** of a single intravitreal injection of SPVN20 gene therapy in subjects with no light perception due to end-stage **rod-cone dystrophy**, who retain dormant foveal cone photoreceptors. This is clinically relevant as it aims to determine the potential of SPVN20 gene therapy to be a viable treatment option for patients with this advanced stage of retinal degeneration, where current therapeutic options are limited.

The clinical trial involves participants diagnosed with **end-stage rod-cone dystrophy**. The study population includes both male and female subjects, with an age range spanning from children to adults. The trial does not specifically target a vulnerable population. The sponsor has not provided information regarding the total number of participants or specific lifestyle considerations such as diet, physical activity, or habits. Additionally, details on the selection process for the trial population and key inclusion or exclusion criteria have not been disclosed.

The clinical trial is designed to evaluate the **safety** and tolerability of a single intravitreal injection of SPVN20 gene therapy in subjects with no light perception due to end-stage rod-cone dystrophy, who retain dormant foveal cone photoreceptors. This is a Phase 1, open-label, dose-escalation study. The trial is expected to commence recruitment on July 15, 2025, and is estimated to conclude by July 15, 2031. Participants will be involved in the study for a duration that aligns with the trial's timeline, subject to their continued eligibility and adherence to the study protocol.

The study will include several key visits: an initial screening visit to determine eligibility, followed by a series of follow-up visits to monitor safety and collect data on the therapeutic effects. The end-of-study visit will conclude the participant's involvement, ensuring all necessary data is collected and any post-treatment assessments are completed. Participants may be withdrawn from the study early if they experience adverse effects that compromise their safety, if they fail to comply with the study protocol, or if they choose to withdraw consent.

The trial will not employ a randomized or double-blind design, as it is an open-label study, meaning both the researchers and participants will be aware of the treatment being administered. The primary focus is on assessing the safety profile of the gene therapy, with secondary objectives likely involving the evaluation of any potential therapeutic benefits. The study's methodology is structured to ensure rigorous monitoring and data collection throughout the trial duration, providing valuable insights into the treatment's impact on this rare and severe condition.

No specific information regarding the experimental medication, including its name, pharmaceutical form, dosage, route, and frequency of administration, is provided in the available data. Consequently, a detailed description of the experimental treatment cannot be formulated based on the current dataset.

Similarly, there is no information available about any non-experimental treatments, such as standard-of-care therapy, placebo, or comparator treatment, used in the study. Therefore, a description of these elements cannot be provided.

Additional relevant information about drug administration, dosing schedules, and participant compliance monitoring is also not included in the data. As such, these aspects cannot be detailed in the current context.

The clinical trial is designed to assess efficacy through a structured evaluation process. The trial is categorized as a Phase 1 study, which typically focuses on assessing safety, tolerability, and pharmacokinetics, but may also include preliminary efficacy assessments. The trial is scheduled to commence recruitment on July 15, 2025, with an estimated completion date of July 15, 2031. Although specific efficacy endpoints are not detailed, Phase 1 trials often utilize various parameters such as **biomarker** levels or symptom improvement scores to gather initial efficacy data. The methods and schedule for measuring, collecting, and analyzing these parameters are not specified, but they generally involve validated scales, laboratory tests, or patient-reported outcomes at predetermined timepoints. The trial will adhere to rigorous scientific standards to ensure the reliability and validity of the efficacy data collected.